Table 5.
Fold changes in skeletal muscle mRNA expression relative to the baseline sample of select angiogenic, inflammatory, and angiostatic mediators in the group exposed to LBH and in the control group (protocol 2)
| Control (33°C) (n = 12) |
LBH (48°C) (n = 11) |
|||
|---|---|---|---|---|
| 30 min | 120 min | 30 min | 120 min | |
| NOS3 | 1.07 ± 0.11 | 1.38 ± 0.25 | 1.16 ± 0.06 | 1.50 ± 0.14 |
| PPARGC1A | 1.18 ± 0.08 | 1.27 ± 0.16 | 1.32 ± 0.06 | 1.21 ± 0.03 |
| MMP2 | 0.99 ± 0.07 | 1.17 ± 0.12 | 0.98 ± 0.07 | 1.07 ± 0.08 |
| TIMP1 | 0.89 ± 0.09 | 1.18 ± 0.22 | 1.12 ± 0.11 | 0.97 ± 0.07 |
| TEK | 1.09 ± 0.11 | 1.30 ± 0.16 | 1.17 ± 0.05 | 1.23 ± 0.06 |
| CXCL12 | 0.98 ± 0.06 | 0.97 ± 0.06 | 0.98 ± 0.03 | 0.93 ± 0.03 |
| NCL | 1.05 ± 0.05 | 1.03 ± 0.04 | 1.09 ± 0.04 | 0.96 ± 0.03 |
| FOXO3 | 1.31 ± 0.06 | 1.34 ± 0.07 | 1.43 ± 0.11 | 1.28 ± 0.11 |
| IL6 | 0.73 ± 0.14 | 0.66 ± 0.14 | 0.65 ± 0.08 | 0.62 ± 0.06 |
| HSPA1A | 0.80 ± 0.05 | 0.73 ± 0.08 | 1.06 ± 0.10 | 0.93 ± 0.08 |
Biopsy samples were taken at baseline and 30 and 120 min following the completion of the interventions.